Sökning: onr:"swepub:oai:prod.swepub.kib.ki.se:112448612" >
Rituximab maintenan...
Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial
-
van Oers, MHJ (författare)
-
Klasa, R (författare)
-
Marcus, RE (författare)
-
visa fler...
-
Wolf, M (författare)
-
- Kimby, E (författare)
- Karolinska Institutet
-
Gascoyne, RD (författare)
-
Jack, A (författare)
-
van't Veer, M (författare)
-
Vranovsky, A (författare)
-
Holte, H (författare)
-
van Glabbeke, M (författare)
-
Teodorovic, I (författare)
-
Rozewicz, C (författare)
-
Hagenbeek, A (författare)
-
visa färre...
-
(creator_code:org_t)
- American Society of Hematology, 2006
- 2006
- Engelska.
-
Ingår i: Blood. - : American Society of Hematology. - 0006-4971 .- 1528-0020. ; 108:10, s. 3295-3301
- Relaterad länk:
-
http://kipublication...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- We evaluated the role of rituximab (R) both in remission induction and maintenance treatment of relapsed/resistant follicular lymphoma (FL). A total of 465 patients were randomized to induction with 6 cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) (every 3 weeks) or R-CHOP (R: 375 mg/m2 intravenously, day 1). Those in complete remission (CR) or partial remission (PR) were randomized to maintenance with R (375 mg/m2 intravenously once every 3 months for a maximum of 2 years) or observation. R-CHOP induction yielded an increased overall response rate (CHOP, 72.3%; R-CHOP, 85.1%; P < .001) and CR rate (CHOP, 15.6%; R-CHOP, 29.5%; P < .001). Median progression-free survival (PFS) from first randomization was 20.2 months after CHOP versus 33.1 months after R-CHOP (hazard ratio [HR], 0.65; P < .001). Rituximab maintenance yielded a median PFS from second randomization of 51.5 months versus 14.9 months with observation (HR, 0.40; P < .001). Improved PFS was found both after induction with CHOP (HR, 0.30; P < .001) and R-CHOP (HR, 0.54; P = .004). R maintenance also improved overall survival from second randomization: 85% at 3 years versus 77% with observation (HR, 0.52; P = .011). This is the first trial showing that in relapsed/resistant FL rituximab maintenance considerably improves PFS not only after CHOP but also after R-CHOP induction.
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
-
Blood
(Sök värdpublikationen i LIBRIS)
Till lärosätets databas
- Av författaren/redakt...
-
van Oers, MHJ
-
Klasa, R
-
Marcus, RE
-
Wolf, M
-
Kimby, E
-
Gascoyne, RD
-
visa fler...
-
Jack, A
-
van't Veer, M
-
Vranovsky, A
-
Holte, H
-
van Glabbeke, M
-
Teodorovic, I
-
Rozewicz, C
-
Hagenbeek, A
-
visa färre...
- Artiklar i publikationen
-
Blood
- Av lärosätet
-
Karolinska Institutet